Kornimate/medical-research-clean huggingface dataset:
the correlation study of hypnotic drugs on the cognitive function of patients with chronic insomnia.

Conditions: Insomnia Chronic

Summary: all the subjects were assessed for sleep quality, anxiety and depression, and cognitive function. based on their previous hypnotic medication history, they were divided into a non-medicine group and a benzodiazepine group，and the group taking non-benzodiazepine drugs.the cognitive effects of different hypnotic drugs on patients were evaluated by comparing sleep related scale and cognitive function scale.

insomnia is one of the most common sleep disorders, with 38.2% of chinese people suffering from sleep disorders. there are many ways to treat insomnia disorders, but drug therapy is the most commonly used method by medical staff. the cognitive effects of sleep drugs vary in numerous studies, depending on the type and dosage of drugs.this study aims to explore the effects of different types of hypnotic drugs on the treatment of insomnia and cognitive function, hoping to improve the sleep quality and living standards of insomnia patients through this study, and also to obtain some cognitive impairment prevention measures related to insomnia, to provide some theoretical basis for clinical treatment.

Eligibility criteria:
inclusion criteria: 1. signed informed consent, male or female ≥18 and ≤75 years old; 2. (icsd-3) proposed the diagnostic criteria for chronic insomnia; 2. did not take hypnotic drugs before the visit; 3. those who took hypnotic drugs before the visit; 4. can understand and comply with the study protocol; exclusion criteria: 1. severe organic disease; 2. any suicidal behavior in the past 10 years; 3. those who cannot communicate normally cannot cooperate to complete the scale test; 4. women who are breastfeeding or pregnant; 5. medical history that the investigator believes could affect the safety of the subject or interfere with the study evaluation; 6. currently diagnosed with sleep apnea, narcolepsy and other sleep disorders; 7. sleep disorders caused by central nervous system diseases, or neurodegenerative diseases such as parkinson's disease, alzheimer's disease, lewy bodies dementia.

Keywords: insomnia cognitive disorder hypnotic memory
the evaluation of the effectiveness, safety and tolerability of treatment, using a psma-lu177, in patients with acc- an open, non-commercial clinical trial

Conditions: Adenoid Cystic Carcinoma

Summary: non-commercial phase 2 clinical trial to evaluate the effectiveness, safety and tolerability of treatment using prostate-specific membrane antigen (psma) labeled with 177lutetium in patients with recurrence and/or metastases in adenoid cystic carcinoma originating from the salivary glands of the head and neck region. patients with psma receptor expression confirmed by pet/ct after administration of 68ga-psma i\&t will be eligible for treatment.

it is planned to enroll 32 patients diagnosed with non-resectable recurrence and/or dissemination in the course of acc, whose general condition and life expectancy justify qualification for diagnosis using psma 68ga and treatment with lutetium (177lu) vipivotide-tetraxetan the study assumes the administration of 6 cycles of treatment (lutetium \[177lu\] vipivotide-tetraxetan) at 6-week intervals. if toxicity occurs, the activity of the next dose of the preparation will be modified or its next administration will be delayed by a maximum of 4 weeks. after completing 6 cycles of therapy, the participant enters the observation phase, which will last until recurrence of the disease is diagnosed or for 2 years after the end of therapy.

Eligibility criteria:
inclusion criteria: * signing the informed consent form to participate in the study * patients with inoperable, locoregionally advanced or metastatic, histopathologically confirmed adenoid cystic carcinoma of salivary gland * age over 18 years * who performance status 0 to 2 * psma expression confirmed by pet/ct using 68ga-psma; * presence of measurable disease according to recist 1.1 criteria * adequate function of: bone marrow, liver, kidneys: bone marrow: neutrophils \>1500x10\^9/l; thrombocytes \>150,000x10\^9/l, hemoglobin \>9 g/dl liver: bilirubin \ 50 ml/min albumin \>2.5 mg/ml * for women of reproductive age: confirmed negative pregnancy test * the need to use of a highly effective method of contraception exclusion criteria: * pregnancy or breastfeeding * lack of effective contraception during childbearing age * patients with metastases to the brain, meninges or heart * severe or significant additional diseases in the opinion of the investigator * urinary tract obstruction and/or hydronephrosis. * concomitant treatment of another cancer * myelosuppressive or nuclear treatment later than 4 weeks after qualification * previous treatment with 177lutetium-labeled psma
efficacy of platelet-rich plasma injection in dry eye syndrome

Conditions: Severe Dry Eye Syndromes; Dry Eye Syndromes

Summary: the investigatror wants to show the efficacy of platelet-rich plasma injection in lacrimal gland to restore the lacrimal secretion in patients presenting aqueous deficiency reponsible for severe dry eye syndrome.

injections in lacrimal gland four times during the study for each patient

Eligibility criteria:
inclusion criteria: * platelet counts, and clotting factors in the standarts * presenting with severe dry keratoconjunctivitis diagnosed by an ophthalmologist exclusion criteria: * patients with significant fibrosis of the conjunctival portion of the lacrimal gland * patients with complete stenosis of both lacrimal meatus in the treated eye

Keywords: dry eye syndromes lacrimal gland platelet-rich plasma aqueuous deficiency
covid-19 tests with saliva specimens

Conditions: Covid19

Summary: upper respiratory swabs, such as the nasopharyngeal (np) swab, have so far been major specimen sources used for the sars-cov-2 molecular test. however, due to the discomfort and invasiveness of np collection, and the expense of personal protective equipment, alternative sampling sources such as saliva are desired. the purpose of this proposed study is: 1) to examine whether saliva can be used as an specimen for the sars-cov-2 molecular test; 2) to test if gingival crevicular fluids is a reliable specimen for the sars-cov-2 antibodies.


Eligibility criteria:
inclusion criteria: * persons referred for covid-19 testing including those with covid-19 symptoms and/or a suspected sars-cov-2 infection or undergoing surveillance testing and * is able to give informed consent * is able to understand oral or written instructions, and * is able to mentally and physically perform self-collection of saliva using the provided collection device. exclusion criteria: * - adults unable to consent * individuals who are not yet adults (infants, children, teenagers) * employees of paradigm lab and the assisted living facilities involved in the study * members of other vulnerable populations
pyrotinib in combination with nab-paclitaxel in patients with her2-positive advanced breast cancer: an exploratory study

Conditions: HER2-positive Breast Cancer

Summary: this clinical trial aim to evaluate the efficacy and safety of pyrotinib in combination with nab-paclitaxel in patients with her2-positive advanced breast cancer.


Eligibility criteria:
inclusion criteria: * 1. age: 18-70 years old，female; 2. pathologically confirmed her2-positive invasive breast cancer by local laboratory with the following requirements: her2 overexpressed or amplified (immunohistochemistry of 3+ or her2 gene amplification by in situ hybridization) 3. imaging examination confirmed recurrent/metastatic breast cancer； 4. patients must have previous treatment with trastuzumab more than 9 weeks; 5. untreated for metastatic/metastatic disease (except for endocrinotherapy); 6. patients with at least one measurable lesions by recist version 1.1； 7. eastern cooperative oncology group (ecog) performance status 0-2； 8. life expectancy greater than or equal to 3 months; 9. participants must have normal organ and marrow function as described below： absolute neutrophil count≥1.5×109/l; platelets≥90×109/l; hemoglobin ≥90g/l； total bilirubin ≤ 1.5 x institutional upper limit of normal (uln)； alt and ast≤2\*uln, but ≤5\*uln with liver metastases; bun and cr≤1.5×uln or creatinine clearance ≥50ml/min left ventricular ejection fraction (lvef) ≥ 50% 10. doctors believe that treatment can bring benefits to patients； 11. participants were willing to join in this study, and written informed consent. exclusion criteria: * 1. a variety of factors influencing oral drugs (after resection of the gastrointestinal, unable to swallow, chronic diarrhea, intestinal obstruction); 2. patients with other malignant tumors within 5 years (except for skin basal cell carcinoma and cervical carcinoma in situ); 3. history of psychiatric drugs abuse or patients with mental disorders; 4. pregnant or lactating women; 5. less than 4 weeks from the last clinical trial 6. the researchers think inappropriate.
impact of pumps on internal thoracic arteries (ipita)

Conditions: Coronary Disease

Summary: cardiopulmonary bypass (cpb) induces a systemic inflammatory response and affects the organ vascular bed. experimentally, the lack of pulsatility alters myogenic tone of resistance arteries and increases the parietal inflammatory response. the purpose of this study was to compare the vascular reactivity and the inflammatory response of the internal thoracic arteries (itas) between patients undergoing coronary artery bypass grafting (cabg) under cpb with a roller pump or with a centrifugal pump.

eighty elective male patients undergoing cabg were selected using one or two internal thoracic arteries under cpb with a roller pump (rp group) or centrifugal pump (cfp group). ita samples were collected before starting cpb (time 1) and before the last coronary anastomosis during aortic cross clamping (time 2). terminal complement complex activation (sc5b-9) and neutrophil activation (elastase) analysis were performed on arterial blood at the same times.

Eligibility criteria:
inclusion criteria: * male patients and elective coronary artery bypass grafting using at least one of the two itas. exclusion criteria: * female patients because their complement activation has been shown to be greater than that in men during surgery under cardiopulmonary bypass ; age \< 18 years; cabg requiring additional valve repair or replacement; emergency surgery and insufficient length of the internal thoracic artery

Keywords: cardiopulmonary bypass pulsatility systemic inflammatory response arterial graft
a double-blind placebo-controlled group comparative study to evaluate the safety and effectiveness of aerosol pentamidine in the prophylaxis of pneumocystis carinii pneumonia in patients with aids post first episode pcp

Conditions: Pneumonia, Pneumocystis Carinii; HIV Infections

Summary: to evaluate and compare the safety, tolerability, and efficacy of biweekly administration of aerosol pentamidine versus placebo when used as a prophylactic agent in patients who have recovered from their first episode of aids-associated pneumocystis carinii pneumonia (pcp).


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * zidovudine (azt). if azt is started during the study, patients must have received = or \> 15 days of aerosol pentamidine before beginning azt. prior medication: allowed: * zidovudine (azt). if azt began prior to study entry, patients must have received = or \> 15 days of azt before beginning aerosol pentamidine. exclusion criteria co-existing condition: patients with the following are excluded: * requiring ongoing active therapy for an opportunistic infection (o.i.) at time of entry or those with either of the following aids-defining o.i.'s prior to entry: * toxoplasmosis. * cryptococcosis. * transfusion dependent (requiring blood transfusion more than once per month). the last transfusion cannot have been given within 7 days of study entry. * pulmonary kaposi's sarcoma (ks). * uncontrolled asthma. * active therapy for tuberculosis. patients with the following are excluded: * requiring ongoing active therapy for an opportunistic infection (o.i.) at time of entry or those with either of the following aids-defining o.i.'s prior to entry: * toxoplasmosis. * cryptococcosis. * transfusion dependent (requiring blood transfusion more than once per month). the last transfusion cannot have been given within 7 days of study entry. * pulmonary kaposi's sarcoma (ks). * uncontrolled asthma. prior medication: excluded within 30 days of study entry: * antiretroviral agents other than zidovudine (azt). * immunomodulating agents. * corticosteroids. active therapy for tuberculosis. patients must: * have aids and recovered from their first episode of pneumocystis carinii pneumonia (pcp). * be at least 2 weeks and no more than 24 weeks status post therapy for acute pcp. * have positive antibody to hiv by a government-approved elisa test kit, or confirmed western blot test. * adequate pulmonary function (vital capacity = or \> 80 percent of predicted; forced expiratory volume (fev), 1 s = or \> 65 percent of total fev; and corrected pulmonary diffusion capacity \> 60 percent of predicted). * free of acute medical problems. active substance abuse.

Keywords: aids-related opportunistic infections pneumonia, pneumocystis carinii pentamidine acquired immunodeficiency syndrome
evaluation of the hypoalgesic effects of transcranial direct current (tdcs) in healthy subjects

Conditions: Pain Modulation

Summary: the main objective of this research is to evaluate and quantify hypoalgesic effects caused by imagination and observation with or without the presence of transcranial direct current (tdcs) in healthy participants. the secondary objective of this research is to evaluate the possible relationships between hypoalgesic effects and different physical and cognitive variables such as the ability to generate motor mental images, mental chronometry and levels of physical activity.


Eligibility criteria:
inclusion criteria: * asymptomatic participants * men and women aged 18 to 65 years exclusion criteria: * insomnia * nausea * headache * pregnant woman * use of painkillers in the last twenty four hours * presence of metal inside the head * pacemaker * wound on the area of electrodes' application * drugs consumer * recent application of transcranial direct stimulation * psychiatric disease who lead the subject to a misunderstand of the study

Keywords: motor imagery transcranial direct current stimulation action observation
guanfacine for the treatment of spatial neglect and impaired vigilance

Conditions: Stroke; Hemispatial Neglect

Summary: to find out if spatial neglect following stroke and brain injury can be reduced using guanfacine, a drug that was shown to improve neglect in two stroke patients in a previous pilot study (malhotra et al, 2006). in this trial, the effects of guanfacine will be examined in a larger number of patients, and there will also be a systematic assessment of whether the drug is only effective in patients with particular patterns of brain damage.

the current study has a double-blind crossover design where patients will receive a single 2mg dose of oral guanfacine and a single dose of placebo. they will receive one of these on day 2 of the study period and the other on day 4. they will be tested daily on days 1 to 5 so that any test repetition or long-term drug effects can be gauged. on days 2 and 4 they will be tested twice-once prior to drug/placebo administration and again 90 minutes after drug/placebo administration. tests will include standard pen-and-paper tasks for neglect as well as computerised tests of sustained attention and visual exploration. in our published pilot study (malhotra et al, 2006) there was a suggestion that patients without damage to frontal cortex were more likely to respond to guanfacine. in the current study we intend to test 10 patients with and 10 patients without frontal damage in order to test this further.

Eligibility criteria:
inclusion criteria: * age 18 or more * greater than 2 weeks following stroke * ability to give consent * evidence of robust visual neglect when tested twice with cancellation tasks. exclusion criteria: * less than 2 weeks following stroke * concomitant illness that may affect interpretation of any findings * labile blood pressure following stroke * systolic bp less than 100 mmhg and / or diastolic less than 70 mmhg * new antihypertensive medication started within last 3 weeks * patients with hepatic or renal dysfunction * patients receiving other medications known to potentiate guanfacine's antihypertensive and hypotensive effects or cause torsade de pointes, specifically antipsychotics (including sultopride, chlorpromazine, thioridazine, amisulpiride, sulpiride, haloperidol), and moxifloxacin, baclofen, verapamil, quinidine, hydroquinidine, dispyramide, amiodarone, dofetilide, ibutilide, sotalol, pimozide, bepridil, cisapride, diphemanil, erythromycin iv, halofantrine, pentamidine, sparfloxacin, vincamine, alfuzosin, prazosin, terazosin, tamsulosin, amifostine * patients with diagnosis of brain tumour * patients with weight less than 55kg * patients who are pregnant * mothers who are breast feeding * patients with severe coronary insufficiency or myocardial infarction in previous 6 months * cognitive impairment, dysphasia or dementia that prevents patient from giving informed consent * severe mental impairment or physical handicap following stroke that prevents patients from giving consent or performing basic (standard clinical) tests for neglect

Keywords: neglect attention vigilance stroke hemineglect unilateral neglect spatial neglect
a study of vemurafenib (ro5185426) in participants with metastatic or unresectable papillary thyroid cancer positive for the braf v600 mutation

Conditions: Neoplasms

Summary: this open-label, multi-center study will evaluate the safety and efficacy of vemurafenib (ro5185426) in participants with metastatic or unresectable papillary thyroid cancer (ptc) positive for the braf v600 mutation and resistant to radioactive iodine therapy. participants will receive vemurafenib 960 milligrams (mg) orally twice daily until progressive disease or unacceptable toxicity occurs.


Eligibility criteria:
inclusion criteria: * adult participants. \>/= 18 years of age * histologically confirmed metastatic or unresectable papillary thyroid cancer for which standard curative or palliative measures do not exist or are no longer effective; participants whose tumors exhibit areas of "other histology" may be enrolled, provided the tumor histology remains predominantly papillary * positive for braf v600 mutation (roche cobas 4800 braf v600 mutation test) * radioactive iodine resistant disease * prior therapy excluding (cohort 1, tki naive) or including (cohort 2, tki experienced) tki * clinically relevant disease progression according to recist criteria within the prior 14 months * eastern cooperative oncology group (ecog) performance status 0 or 1 * adequate hematological, renal and liver function exclusion criteria: * histological diagnosis other than papillary ptc, including squamous cell variants of ptc or ptc with areas of squamous metaplasia * active or untreated central nervous system metastases * history of or known carcinomatous meningitis * anticipated or ongoing administration of any anti-cancer therapies other than those administered in the study * active squamous cell skin cancer that has not been excised or adequately healed post excision * previous treatment with any agent that specifically and selectively targets the mek or braf pathway * prior radiotherapy to the only measurable lesion * clinically relevant cardio-vascular disease or event within the prior 6 months
combined low-dose isotretenion and long-pulsed 1064 nd-yag laser in the treatment of acne erythema

Conditions: Acne Vulgaris

Summary: acne erythema consists of telangiectasia and erythematous papules, without a comedo, which occurs as a result of inflammatory acne. moreover, although acne erythema is common in acne patients, no satisfactory medical or surgical treatment is available for this condition. some acne erythema lesions may improve with time, but the persistent acne erythema, which is experienced by most patients, is cosmetically unacceptable and leads to frustration and psychological distress.

up to the present time, there have been several studies on the clinical efficacy of different laser modalities for acne treatment. pulsed dye laser (pdl), 585 or 595 nm, has been demonstrated as one of the effective treatment options another laser long-pulsed neodymium: yttrium-aluminum-garnet (nd:yag) laser with 1064 nm has been commonly used for skin rejuvenation. nevertheless, the efficacy of this laser for acne treatment has been shown in some studies and case reports. the therapeutic effect on acne lesions is believed to be mediated by the selective photothermolysis of vessels, the upregulation of tgf-β, the reduction of interleukin-8 (il-8) and toll-like receptors-2 (tlr-2), and the thermal destruction of sebaceous glands. isotretinoin remains the mainstay of acne treatment. no doubt, the side effects of this effective drug holds physicians back from jumping to prescribe it. recent data suggested that lower doses (0.25 mg/kg/day) may lead to fewer side effects. and fewer flares. clearing the use of oral isotretinoin in combination with other procedures has expanded our therapeutic options to obtain better control.

Eligibility criteria:
inclusion criteria: * 1. adult patients with acne 2. patients of both sexes. 3. willing to sign an informed consent exclusion criteria: - 1. patients who were taking concomitant acne medication 2. patients had a history of topical or systemic therapy use for acne for the past 6 months, 3. patients with a history of photosensitivity reactions 4. patients with any renal or hepatic compromise or any preexisting hyperlipidemia. 5. pregnant females as well as females who intend to become pregnant during treatment 6. hypertrophic scar or keloid. 7. active or recurrent herpes simplex.